Hereditary Fructose Intolerance: Aldolase B Deficiency Postprandial Hypoglycemia Hepatic Injury and Dietary Management

Home › Gastroenterology › Hereditary Fructose Intolerance

Hereditary Fructose Intolerance: Aldolase B Deficiency Postprandial Hypoglycemia Hepatic Injury and Dietary Management

An autosomal recessive inborn error of fructose metabolism caused by biallelic loss-of-function mutations in ALDOB encoding aldolase B — clinically defined by acute postprandial hypoglycemia, vomiting, lactic acidosis, hyperuricemia, and acute hepatic injury triggered by fructose, sucrose, or sorbitol ingestion, with lifelong fructose-free diet as the disease-defining therapy and a profound aversion to sweet foods that is itself protective in many affected individuals.

~1 / 20–30kPrevalence in Western populations
Weaning ageTypical onset (with fructose introduction)
~70%Of mutations are A149P (Western)
AcuteIV fructose-containing fluid is fatal in HFI

S1. Pathophysiology and Aldolase B Biology

Hereditary fructose intolerance (HFI) — first described by Chambers and Pratt in 1956 — is an autosomal recessive inborn error of carbohydrate metabolism caused by biallelic loss-of-function mutations in the ALDOB gene encoding aldolase B (fructose-1,6-bisphosphate aldolase), one of three tissue-specific aldolase isoenzymes (aldolase A in muscle and red blood cells; aldolase C in brain). Aldolase B is expressed predominantly in liver, kidney, and intestinal mucosa where it catalyzes two reactions in fructose and glycolysis metabolism: the cleavage of fructose-1-phosphate to dihydroxyacetone phosphate and glyceraldehyde, and the reversible cleavage of fructose-1,6-bisphosphate in glycolysis.

The clinical consequences of aldolase B deficiency unfold immediately on fructose exposure and reflect both what accumulates upstream of the enzymatic block and what fails to be produced downstream:

Aldolase B Deficiency Metabolic Cascade in Hereditary Fructose Intolerance Vertical cascade beginning with dietary fructose phosphorylated by fructokinase to fructose-1-phosphate, which accumulates behind the deficient aldolase B enzymatic block, then branches into four downstream consequences converging on the acute clinical picture. Aldolase B Deficiency: The Metabolic Trap Upstream accumulation and downstream failure after fructose ingestion Dietary FRUCTOSE fructokinase (fast) Fructose-1-phosphate accumulates up-up x ALDOB block (aldolase B) F1P to DHAP + glyceraldehyde FAILS Four downstream consequences 1. Phosphate trap Pi sequestered by F1P to ATP depletion to hepatic injury 2. Gluconeogenesis inhibited – no new glucose synthesis to hypoglycemia 3. Glycogenolysis blocked – glycogen not mobilized deepens hypo 4. Renal tubule proximal ALDOB cells same block Fanconi-like RTA ACUTE ATTACK – within 30 to 90 minutes of ingestion Hypoglycemia, lactic acidosis, hyperuricemia, vomiting, acute liver & renal injury Tissue specificity is why injury is liver / kidney / gut selective: Aldolase B (ALDOB) – liver, kidney proximal tubule, intestinal mucosa: affected Aldolase A – muscle & red blood cells: unaffected (glycolysis preserved) Aldolase C – brain: unaffected
  1. Accumulation of fructose-1-phosphate in hepatocytes traps inorganic phosphate, depleting cellular ATP and producing severe acute hepatic injury, lactic acidosis, hyperuricemia, and renal tubular dysfunction.
  2. Inhibition of gluconeogenesis from the upstream accumulation produces acute hypoglycemia within 30–90 minutes of fructose ingestion, particularly in fasted or carbohydrate-depleted patients.
  3. Inhibition of glycogenolysis from sequestration of phosphate compounds prevents glucose mobilization from hepatic glycogen, deepening the hypoglycemia.
  4. Renal tubular acidosis and proximal tubule dysfunction arise from a parallel mechanism in renal aldolase B-expressing tubular cells.

The acute clinical picture in an unrecognized infant given fruit, juice, or sucrose-containing formula is dramatic and life-threatening: vomiting, lethargy, profound hypoglycemia, lactic acidosis, hyperuricemia, hepatomegaly, and acute liver and renal failure. In contrast, older children and adults with established HFI usually develop a strong protective aversion to sweet foods early in life — fruits, sweets, sucrose-containing products taste unpleasant or are immediately followed by nausea and discomfort — and unintentionally restrict their own dietary fructose intake. This aversion is so consistent that “dental decay-free child or adult who refuses sweets” is a classic diagnostic clue.

Hereditary Fructose Intolerance: Metabolic Block, Acute Symptoms, Forbidden Sugars, Dietary Management Four-panel diagram showing ALDOB metabolic block with downstream consequences, acute symptom constellation, forbidden sugar list, and lifelong dietary algorithm A. Aldolase B Metabolic Block Fructose ←fructokinase F-1-P ↑↑ trapped ⚠ ALDOB DEFICIENT DHAP + glycer. Consequences: • Pi trapped → ATP↓ • Hepatic injury • Block gluconeogen • Block glycogenol → HYPOGLYCEMIA • Lactic acidosis • Hyperuricemia • Tubular dysfunction Tissue specificity: Liver + kidney + intestine express ALDOB Muscle/RBC use ALDOA (unaffected) B. Acute Attack Constellation Hypoglycemia (within 30–90 min) Vomiting, lethargy, irritability Lactic acidosis + hyperuricemia Acute liver injury + hepatomegaly Renal tubular dysfunction Failure to thrive (chronic) Strong sweet aversion (protective) Onset at weaning (fruit/juice introduction) ⚠ IV fructose contraindicated — fatal in HFI C. Forbidden Sugars FRUCTOSE — fruit, honey, fruit juice SUCROSE — table sugar, candy, baking (glucose + fructose disaccharide) SORBITOL — sugar-free gum, mannitol (metabolized to fructose by sorbitol DH) High-fructose corn syrup — beverages SAFE: glucose, lactose, maltose, starch — meats, dairy, eggs, grains, vegetables Hidden fructose in medications + vaccines D. Lifelong Dietary Management 1. Strict fructose/sucrose/sorbitol elim 2. Vitamin C + folate supplementation 3. Medication audit q visit 4. Emergency ID + IV fluid warning Pre-op: avoid fructose-containing fluids Anesthesia: use D5W/normal saline only

The genetic spectrum is dominated by a small number of common founder mutations in Western populations. The p.A149P (A149P) variant accounts for approximately 70% of pathogenic alleles in Northern European populations, with smaller contributions from p.A174D, p.N334K, and others. Most patients are homozygous A149P or compound heterozygous A149P/other-variant. Different ethnic populations show different founder mutations. Targeted mutation analysis is therefore a practical first-line genetic test, with full ALDOB sequencing reserved for cases where targeted testing is negative.

S2. Diagnostic Criteria and Safe Workup

Diagnosis combines compatible clinical features (acute illness on fructose exposure, postprandial symptoms, sweet aversion, family history) with genetic confirmation by ALDOB targeted mutation analysis or full sequencing. The historical “fructose tolerance test” — IV fructose administration to provoke hypoglycemia — is now strictly contraindicated because it can be fatal in affected individuals.

InvestigationFinding in HFIClinical role
ALDOB targeted mutation analysis (A149P + other common variants)Pathogenic biallelic variants — most commonly A149P homozygous or compound heterozygousFirst-line definitive diagnostic test
Full ALDOB gene sequencingPathogenic variants when targeted negativeSecond-line confirmation
Liver function tests during acute episodeElevated AST, ALT, prolonged PT, hypoglycemia, hyperammonemia in severe casesAcute presentation assessment
Lactate, uric acid, magnesium, phosphateLactic acidosis, hyperuricemia, hypophosphatemia, hypomagnesemia during acute episodeBiochemical signature of acute attack
Glucose monitoring during acute episodeHypoglycemia (often profound, <40 mg/dL)Confirms hypoglycemic component
Urinalysis with tubular function panelProximal RTA, glycosuria, generalized aminoaciduria (Fanconi-like syndrome) during acute episodeIdentifies renal tubular involvement
Liver biopsy with aldolase B activity assayReduced aldolase B activity; histology shows steatosis and glycogen depletionHistorical gold standard; rarely needed now
IV fructose tolerance testWas historical diagnostic; produces severe acute illnessSTRICTLY CONTRAINDICATED — fatal in affected patients
Fructose breath testNot appropriate for HFI diagnosis; may produce severe symptomsContraindicated in suspected HFI
Family history (3-generation pedigree)Autosomal recessive pattern, consanguinitySupports diagnosis; identifies at-risk siblings
Dental examinationStrikingly absent dental caries even in adults (sweet avoidance)Classic supportive feature
Detailed dietary historyLifelong aversion to fruits, sweets, sucrose; symptomatic response to fructose-containing foodsImportant clinical clue

The shift to genetic confirmation rather than provocation testing represents the most important diagnostic safety advance of the past two decades. Suspected HFI in any patient — child or adult presenting with characteristic features, family member of an affected individual, incidental finding of A149P heterozygosity on broader genetic testing — should proceed directly to ALDOB targeted mutation analysis rather than functional or provocation testing. Hospital protocols and laboratory request forms should specifically include HFI in the differential to ensure that targeted testing is offered.

Absolute contraindication to IV fructose: IV fructose-containing fluids (rare in modern practice but still encountered, particularly in older inpatient TPN formulations and in some international settings) can produce fatal acute hepatic failure in HFI patients within hours. Pre-anesthesia, pre-procedure, and inpatient fluid orders must specify glucose-only (D5W, D10W, normal saline) when HFI is known or suspected. Patient emergency identification (MedicAlert bracelet) is essential because affected adults presenting unconscious or unable to communicate cannot warn medical staff of the contraindication.

S3. Treatment Strategy and Lifelong Dietary Management

Treatment is dietary — strict lifelong elimination of fructose, sucrose, and sorbitol from food, beverages, and medications. The disease has no pharmacologic disease-modifying therapy; the metabolic block cannot be bypassed because aldolase B is essential for fructose metabolism.

Lifelong Dietary Management Ladder and Sugar Safety Map for Hereditary Fructose Intolerance Left panel is a four-tier management ladder from strict elimination diet up through supplementation, medication and IV fluid audit, to emergency identification and glucose-only fluids. Right panel maps forbidden sugars against safe carbohydrates and safe sweeteners. Management: Diet Is the Whole Therapy No drug bypasses the block – lifelong avoidance plus safeguards Four-tier management ladder 1 . FOUNDATION Strict lifelong fructose / sucrose / sorbitol-free diet – disease-defining 2 . NUTRITION Vitamin C ~100 mg/day + folate; fructose-free multivitamin 3 . VIGILANCE Medication + IV fluid audit each visit (hidden sorbitol / sucrose) 4 . SAFETY NET Medical-alert ID + glucose-only IV (D5W/D10W/saline) peri-op Sugar safety map FORBIDDEN – trigger acute attacks Fructose – fruit, juice, honey, agave Sucrose – table sugar (glucose+fructose) Sorbitol to fructose via sorbitol DH High-fructose corn syrup – beverages SAFE – provide all dietary carbohydrate Glucose – snacks, IV fluids, tablets Lactose – milk, dairy (no added sugar) Maltose, starch – rice, pasta, bread Safe sweeteners (not metabolized to fructose): saccharin, sucralose, aspartame, stevia Caution: sweeter vegetables (carrot, pea, beet) in bulk Outcome with strict adherence: normal growth, normal life expectancy, caries-free Key point: the protective sweet aversion makes adherence intuitive – most patients self-restrict fructose. Residual risk is hidden fructose in medications and IV fluids, not food.
Compliance is generally excellent because the protective sweet aversion makes adherence intuitive for most affected individuals — they find fructose-containing foods unpleasant or symptom-provoking.

Forbidden sugars

  • Fructose — fruits (all), fruit juices, honey, agave syrup, fruit-flavored products, high-fructose corn syrup beverages, dried fruits.
  • Sucrose — ordinary table sugar (a disaccharide of glucose + fructose, hydrolyzed to fructose during digestion), virtually all “sweetened” commercial products, baked goods, candies, soft drinks, breakfast cereals with added sugar, condiments and sauces containing sugar.
  • Sorbitol — sugar-free gum and candy (sorbitol is metabolized to fructose by sorbitol dehydrogenase), some medications and infant formulas using sorbitol as sweetener or stabilizer.
  • Hidden fructose — many medications use sucrose, sorbitol, or fructose as binding agents, fillers, or sweeteners; some vaccines and parenteral nutrition formulations contain sucrose or sorbitol. Pharmacist review of all medications is essential.

Safe carbohydrates

Glucose, lactose (milk sugar), maltose, and starch are safe and provide all needed dietary carbohydrate. Safe foods include meats, fish, eggs, dairy products (milk, cheese, yogurt without added sugar), grains (rice, pasta, bread without added sugar or fruit), most vegetables (with caution about a few sweeter vegetables like carrots, peas, beetroot in large quantities), and glucose-based snacks and beverages.

Nutritional adjuncts

Because fruits are eliminated, vitamin C supplementation at approximately 100 mg/day is appropriate. Folate supplementation may also be needed because some folate-rich foods are co-eliminated. Multivitamin supplementation should be fructose-free and screened with a dietitian. Multivitamins specifically formulated for HFI exist.

Medication and parenteral management

Every prescription, over-the-counter, and supplement formulation should be reviewed for fructose, sucrose, or sorbitol content. Liquid pediatric formulations are particularly likely to contain sucrose or sorbitol. IV fluids must be fructose-free — glucose-based (D5W, D10W) or saline. Anesthesia and surgical fluid orders must be explicitly fructose-free. Patient identification (MedicAlert bracelet, wallet card, electronic medical record allergy field) is essential.

Pediatric management and weaning

For children with confirmed HFI, structured weaning with fructose-free solid foods is essential. Lactose-containing infant formula is appropriate; sucrose-containing or fruit-juice-flavored formulas are contraindicated. Pediatric dietitian involvement is recommended throughout childhood to ensure adequate nutrition with strict avoidance.

ApproachBest evidence nichePractical positioning
Lifelong fructose/sucrose/sorbitol-free dietPrimary therapyDisease-defining; no pharmacologic alternative
Pediatric dietitian involvementChildhood weaning + growthFrom diagnosis through adolescence
Adult dietitian periodic reviewOngoing adherence + nutritional adequacyAnnual or biennial
Vitamin C supplementationFruit-elimination consequence~100 mg/day; fructose-free formulation
Folate supplementationIf dietary folate suboptimalSelected supplementation
Medication audit for fructose/sucrose/sorbitolContinuous lifelong responsibilityPharmacist + clinician review
Glucose-only IV fluidsAcute and perioperative careMandatory — explicitly ordered
Medical alert ID + emergency cardUnconscious or non-communicative emergenciesEssential for adult patients
Acute attack management (glucose, supportive)Inadvertent exposureIV glucose to correct hypoglycemia + supportive care
Genetic counselingFamily planning; sibling screeningAt diagnosis and reproductive ages
Pre-pregnancy and pregnancy managementFetal nutrition in affected mothersMultidisciplinary metabolic and obstetric input

S4. Monitoring and Long-Term Outcomes

Surveillance focuses on adherence assessment, nutritional adequacy, hepatic and renal monitoring, and identification of inadvertent fructose exposures.

DomainRecommended intervalTrigger for intervention
Dietary adherence review with dietitianAnnually (children); biennially (adults)Identified gaps → counseling and reinforcement
Liver function tests (AST, ALT, GGT)AnnuallyPersistent elevation → review for hidden fructose
Renal function (creatinine, urinalysis)AnnuallyTubular dysfunction → review for exposures
Lipid panel, uric acidAnnually in adultsStandard cardiovascular surveillance
Growth assessment (pediatric)Each pediatric visitFailure to thrive → dietary intensification
Vitamin status (C, folate, broader if indicated)Annually or as indicatedDeficiency → supplement adjustment
Medication audit at each visitEvery prescription changeNew fructose-containing agent → substitute
Emergency identification updateAnnually + with address/medical changesLost or outdated → replace
Family screening for siblingsAt diagnosisIdentification of affected siblings → enroll in care
Genetic counseling at reproductive agesAs appropriateFamily planning support
Hepatic ultrasoundPeriodic adult assessmentDetects steatosis or unexpected hepatic changes

Long-term outcomes with strict dietary adherence are excellent. Most affected individuals achieve normal growth, normal life expectancy, and minimal disease-related morbidity. The protective sweet aversion that develops early in life supports adherence, and the absence of dental caries that this aversion produces is itself a recognized supportive feature. Inadvertent fructose exposures from hidden sources in medications or unrecognized food ingredients can produce acute attacks at any age, making continued vigilance lifelong rather than a phase of childhood management.

S5. Clinical Commentary and Referral Triggers

The most clinically consequential reframe in hereditary fructose intolerance over the past three decades has been the shift from functional and provocation diagnostic testing — which carried fatal risk in affected patients — to safe genetic confirmation through ALDOB targeted mutation analysis. Any suspected HFI in any patient should proceed directly to genetic testing rather than IV fructose tolerance test, fructose breath test, or empirical dietary challenge, all of which can produce severe or fatal acute illness in confirmed disease.

The second clinical reframe is the recognition that adult presentations of HFI exist — patients who self-managed through lifelong sweet aversion and never received formal diagnosis, often identified incidentally through genetic testing for other indications, family screening after a child is diagnosed, or unexpected acute illness from a fructose-containing IV fluid or medication. Adult presentations highlight the importance of identifying the diagnosis even in apparently healthy individuals because of the perioperative and acute care implications.

When to escalate to metabolic, hepatology, or genetics center:
  • Newly suspected or confirmed HFI — for comprehensive workup and family counseling
  • Pediatric weaning planning with fructose-free dietary instruction
  • Acute presentation with inadvertent fructose exposure
  • Pre-anesthesia or pre-operative planning in known HFI patient
  • Family screening of siblings or extended family
  • Pregnancy management in affected mother
  • Unexplained adult hepatomegaly, hypoglycemia, or tubular dysfunction with possible occult HFI
  • Medication review for fructose/sucrose/sorbitol content in complex regimens

Practice Insights — Synthesized Patterns for Hereditary Fructose Intolerance Care

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.) Across published HFI case series and metabolic clinic experience, the disease’s two most consistent pitfalls are the use of contraindicated fructose-containing IV fluids in unrecognized adult HFI patients during perioperative or acute care — producing severe iatrogenic injury — and the unnecessary distress of incomplete medication review when patients are prescribed liquid formulations containing sorbitol or sucrose without recognition of the HFI implication. Experienced practice has reframed HFI as primarily a “lifelong vigilance against hidden fructose in IV fluids and medications” disease, with the dietary management generally well-handled by the protective sweet aversion.

What the Guidelines Underweight

Experienced metabolic clinicians have learned that medication-related fructose exposure is the most common source of inadvertent acute attacks in adolescents and adults, not dietary indiscretion. Liquid pediatric formulations, some adult medications using sorbitol as a sweetener, and rare parenteral formulations containing sucrose or fructose all pose risks that dietary education alone does not address. A structured medication audit at every clinical encounter, with the pharmacist explicitly informed of the HFI diagnosis, is established practice.

Patterns That Repeat Across Series

The recurring iatrogenic injury pattern in published case series is an adult HFI patient — sometimes previously undiagnosed and managing the disease through sweet aversion alone — admitted for surgical or medical care, receiving IV fructose-containing fluids (rare in modern practice but still encountered in older formulations and some international settings), and developing acute hepatic and renal failure within hours. Experienced practice has prioritized medical alert identification and explicit “no fructose” markers in electronic medical records to reduce this risk.

Bedside Heuristic

The established three-question heuristic for any unexplained acute hypoglycemia with vomiting and hepatic injury in a child after a meal is: (a) was there fruit, fruit juice, sweet food, or sucrose-containing food in the preceding 30–90 minutes, (b) is there family history of recurrent unexplained childhood illness or selective sweet aversion, and (c) is there absent dental caries despite age. Affirmative answers should trigger immediate ALDOB targeted mutation analysis and complete fructose avoidance pending results.

Illustrative Scenario — Adult HFI Recognized at Pre-Operative Assessment

(Composite teaching scenario assembled from published patterns; not an individual patient.)

An illustrative scenario from the literature describes a young adult presenting for elective surgery with a lifelong history of “strong dislike of fruits and sweets” that the patient and family had never recognized as medically significant. Pre-operative dietary screening prompted the anesthesiologist to ask specifically about post-prandial symptoms after sweet foods, which revealed lifelong nausea after any fruit ingestion. Targeted ALDOB mutation analysis was obtained and returned homozygous for A149P, establishing HFI diagnosis. Surgical fluids were modified to glucose-saline only, peri-operative medications were audited for sorbitol or sucrose content, and post-operative recovery was uneventful. The patient was enrolled in metabolic clinic follow-up and provided with medical alert identification.

What this scenario teaches: any patient describing lifelong selective sweet aversion combined with post-sweet symptom history warrants ALDOB targeted mutation analysis, and pre-anesthesia screening should explicitly inquire about sweet aversion and post-prandial symptoms — the diagnosis materially changes peri-operative fluid and medication choices.

Practice Pattern Refinements drawn from published HFI care:
  1. Genetic testing rather than provocation testing. Established practice obtains ALDOB targeted mutation analysis as first-line diagnostic test for suspected HFI, with full sequencing reserved for negative targeted testing. The historical IV fructose tolerance test is strictly contraindicated because of fatal risk in affected patients.
  2. Structured medication audit at every visit. Refined practice reviews every prescription, OTC product, and supplement for fructose, sucrose, or sorbitol content at every clinical encounter, with pharmacist involvement when complex regimens are present — medication-related exposures account for most inadvertent acute attacks in adolescents and adults.
  3. Medical alert identification mandatory. Experienced practice considers medical alert bracelet or equivalent identification essential for adult HFI patients because peri-operative and acute care fluid orders can include fructose-containing solutions if the diagnosis is not communicated when the patient is unable to advocate.
  4. Pre-anesthesia explicit “no fructose” order. Refined practice ensures that pre-operative and intra-operative orders explicitly specify fructose-free fluids (D5W, D10W, normal saline) and that anesthesia team is informed of the diagnosis at the pre-anesthesia visit, not on the day of surgery.

S7. Frequently Asked Questions

What happens biochemically when an HFI patient ingests fructose?
Fructose ingested by an HFI patient is rapidly phosphorylated by fructokinase to fructose-1-phosphate (F1P) in liver, kidney, and intestinal mucosa cells. Aldolase B normally cleaves F1P to dihydroxyacetone phosphate and glyceraldehyde, but in HFI this step is blocked, allowing F1P to accumulate to high cellular concentrations. F1P accumulation traps inorganic phosphate (depleting cellular ATP), inhibits gluconeogenesis (preventing glucose mobilization from non-carbohydrate sources), and inhibits glycogenolysis (preventing glycogen breakdown to glucose). The combined effect is acute hypoglycemia within 30–90 minutes, accompanied by lactic acidosis, hyperuricemia, acute hepatic injury, and renal tubular dysfunction.
Why is sucrose forbidden in HFI?
Sucrose is a disaccharide composed of one glucose and one fructose molecule linked by a glycosidic bond. Intestinal sucrase rapidly hydrolyzes ingested sucrose to its component monosaccharides, releasing free fructose into circulation just as if pure fructose had been ingested. The fructose component then enters the same metabolic pathway that produces acute illness in HFI. Sucrose — table sugar — is therefore equally dangerous as pure fructose for HFI patients, and the much wider distribution of sucrose in foods (compared with isolated fructose) makes sucrose avoidance the more practically challenging dietary task.
Why is sorbitol forbidden?
Sorbitol — a sugar alcohol used as a sweetener in sugar-free gums, candies, some medications, and a few infant formulas — is metabolized by sorbitol dehydrogenase to fructose in the liver. From the HFI patient’s metabolic perspective, sorbitol ingestion is equivalent to fructose ingestion with a brief delay for the dehydrogenase step. Mannitol, similarly, has potential to convert to fructose. All sugar alcohols should be reviewed and generally avoided in HFI patients, with substitute sweeteners (saccharin, sucralose, aspartame, stevia) being safe alternatives because they are not metabolized to fructose.
Why are HFI patients typically caries-free?
The protective sweet aversion that develops in HFI patients early in life — fruits, candies, sweet beverages are unpleasant or produce immediate post-prandial symptoms — leads to lifelong avoidance of most cariogenic foods. Dental caries primarily result from oral bacterial metabolism of sucrose and other simple sugars producing acid that demineralizes enamel; absence of these substrates eliminates the substrate-driven component of caries development. The strikingly caries-free dentition in an adult who reports lifelong sweet aversion is a classic supportive diagnostic feature of HFI and warrants genetic testing in any patient presenting this pattern alongside other suggestive features.
What is the difference between HFI and fructose malabsorption?
Hereditary fructose intolerance (HFI) and fructose malabsorption are entirely different conditions that share only the word “fructose.” HFI is a rare autosomal recessive inborn error of metabolism caused by ALDOB mutations; ingested fructose enters the cells but cannot be metabolized, producing acute hepatic and metabolic injury. Fructose malabsorption is a common functional condition where fructose absorption in the small intestine is incomplete, with unabsorbed fructose producing osmotic diarrhea and gas without systemic illness — patients can eat fructose, just with gastrointestinal discomfort. The hydrogen breath test that diagnoses fructose malabsorption is contraindicated in HFI because the fructose load triggers acute systemic illness. Confusing these two conditions in clinical practice can have serious consequences.
Why is IV fructose contraindicated in HFI?
IV fructose-containing fluids bypass the protective gastrointestinal threshold and intestinal regulation, delivering fructose directly into the hepatic circulation at high concentrations. The resulting fructose-1-phosphate accumulation in hepatocytes is rapid and severe — phosphate trapping and ATP depletion produce acute hepatic injury that can progress to fulminant hepatic failure within hours. Pre-genetic-testing era literature documents fatal outcomes from IV fructose in undiagnosed HFI patients receiving fructose-containing total parenteral nutrition or other formulations. Although IV fructose is rare in modern clinical practice, awareness of this absolute contraindication remains essential because some older formulations, infrequently used preparations, and international practice variations still pose risk.
What is the recurrence risk in pregnancy?
HFI is autosomal recessive with biallelic ALDOB mutations. Heterozygous carriers (parents and approximately half of siblings of an affected individual on average) are unaffected. For pregnancies of two carrier parents, each pregnancy has 25% probability of an affected child, 50% probability of a heterozygous carrier child, and 25% probability of an unaffected non-carrier child. Most cases occur sporadically without family history because the population carrier frequency is modest; consanguineous unions and certain founder populations show substantially elevated incidence. Genetic counseling at the time of diagnosis is appropriate to support family planning, prenatal testing options for at-risk pregnancies, and sibling screening.

Leave a Reply

Your email address will not be published. Required fields are marked *